Actively Recruiting
Genotyping of Ebus-tbna Supernant Cell-free Dna in Nsclc
Led by University Hospital, Toulouse · Updated on 2025-04-03
50
Participants Needed
1
Research Sites
247 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The wide uptake of "liquid biopsy" diagnostics in the care of advanced cancer patients highlights the desire for improved access to tumor allowing accurate tumor genotyping (1). Genotyping of plasma cfDNA is now routine for detection of EGFR driver mutations at diagnosis of NSCLC, or for detection of the EGFR T790M mutation after TKI resistance, and is an emerging approach for the detection of other drivers (HER2 or BRAF mutations, ALK or ROS1 fusions…) (2) or the estimation of tumor mutation burden (TMB) (3). However, the most sensitive plasma genotyping platforms still have a sensitivity of only 70%-80%, such that a negative result requires tissue biopsy confirmation.
CONDITIONS
Official Title
Genotyping of Ebus-tbna Supernant Cell-free Dna in Nsclc
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age > 18 years-old
- Patients planned for an EBUS-TBNA for suspicion of stage IV lung cancer with PET-positive mediastinal nodes (Cohort 1)
- Patients with stage IV NSCLC having EGFR, BRAF, HER2, MET mutations or ALK, RET, ROS1 rearrangements and acquired resistance to targeted therapy (Cohort 2)
- Performance status 0-3
- Provided informed consent
You will not qualify if you...
- Refusal to participate
- Patient under legal tutelage
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nicolas Guibert
Toulouse, France
Actively Recruiting
Research Team
N
Nicolas Guibert, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here